Details of the Drug Combinations

General Information of This Drug (ID: DM1TKG4)

Drug Name
RDEA3170   DM1TKG4
Indication
Disease Entry ICD 11 Status REF
Hyperuricaemia 5C55.Y Phase 2 [1]
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

6 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
RDEA3170 + Allopurinol DCBEYYR Allopurinol Chronic Kidney Disease [2]
RDEA3170 + Rifampicin DCTK4K9 Rifampicin Chronic Kidney Disease [2]
RDEA3170 + Allopurinol DCDFC4I Allopurinol Chronic Kidney Disease [3]
RDEA3170 + Febuxostat DCWDX6A Febuxostat Asymptomatic Hyperuricemia [4]
RDEA3170 + Allopurinol DC7T2GK Allopurinol Chronic Kidney Disease [5]
RDEA3170 + Febuxostat DCGPRCC Febuxostat Asymptomatic Hyperuricemia [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DrugCom(s)

References

1 ClinicalTrials.gov (NCT02078219) Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04532918) Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
3 ClinicalTrials.gov (NCT03836599) A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects
4 ClinicalTrials.gov (NCT03316131) A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
5 ClinicalTrials.gov (NCT03990363) A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia